HGH vs Peptides: Costs, Side Effects, and Which One to Choose

How They Work: Direct Replacement vs. Stimulated Release

Synthetic HGH bypasses the hypothalamic-pituitary axis entirely. You inject exogenous growth hormone, and blood GH levels rise immediately and proportionally to the dose. This is powerful but creates a problem: your pituitary gland detects the elevated GH and reduces its own production (negative feedback). Long-term use can suppress natural GH secretion.

GH-releasing peptides work upstream. GHRH analogs (CJC-1295, sermorelin) mimic the hypothalamic signal that tells your pituitary to release GH. GHRPs (ipamorelin, GHRP-2, GHRP-6) amplify that signal by binding ghrelin receptors on pituitary somatotrophs. Because the pituitary still controls the release, your body's feedback loops remain intact — GH pulses follow a more natural pattern, and the risk of supraphysiological spikes is lower.

Side-by-Side Comparison

Side Effects and Safety

Synthetic HGH risks: The side effect profile is well-documented from decades of clinical use. Common effects include joint pain, edema (fluid retention), carpal tunnel syndrome, and insulin resistance. Chronic supraphysiological dosing can cause acromegaly — pathological growth of hands, feet, jaw, and internal organs including the heart. A 2023 Cleveland Clinic review notes that adults with acromegaly face increased risk of type 2 diabetes, hypertension, and cardiovascular disease. The insulin resistance effect is particularly concerning: GH directly antagonizes insulin signaling, and long-term HGH therapy requires monitoring of fasting glucose, HbA1c, and fasting insulin.

Peptide therapy risks: Because peptides work through the pituitary's own regulatory system, the ceiling for GH release is lower. Ipamorelin — the most selective GHRP — does not raise cortisol or prolactin at any dose (Raun et al., 1998). Less selective peptides like GHRP-6 cause intense hunger via ghrelin activation, and GHRP-2 can modestly elevate cortisol and prolactin. Injection site reactions (redness, irritation) are the most common side effect across all GH peptides.

Cost Breakdown

Cost is often the deciding factor. Prescription somatropin (brand names: Norditropin, Genotropin, Humatrope, Omnitrope) runs $1,000–$5,000 per month depending on dose, brand, and insurance coverage. At typical anti-aging doses (1–2 IU/day), expect $1,200–$2,500/month — that's $14,400–$30,000 per year before lab monitoring costs.

Peptide therapy through a compounding pharmacy typically costs $150–$500/month for a CJC-1295/ipamorelin protocol, including the peptide vials, syringes, and bacteriostatic water. Annual cost: $1,800–$6,000. Some clinics offer subscription models that include quarterly labs.

Important caveat: "research-grade" peptides sold outside the compounding pharmacy system are cheaper ($30–$100/vial) but carry quality and purity risks — no third-party testing, no regulatory oversight, and no recourse if the product is underdosed or contaminated.

Who Should Use What

Consider synthetic HGH if: You have a diagnosed adult growth hormone deficiency (confirmed by stimulation testing), severe GH depletion from pituitary surgery/radiation, or a condition where HGH is FDA-indicated. In these cases, direct replacement is medically appropriate and typically covered by insurance.

Consider peptide therapy if: You're optimizing from a normal baseline — aiming to improve body composition, sleep quality, recovery, or skin elasticity without clinical GH deficiency. Peptides offer a lower-risk, lower-cost entry point that preserves your natural GH axis. The CJC-1295 + ipamorelin stack is the most common starting protocol.

Neither is appropriate if: You have active cancer or a history of hormone-sensitive malignancy (both GH and IGF-1 are mitogens), uncontrolled diabetes, or active proliferative retinopathy.